Surescripts finally found a buyer! TPG (formerly Texas Pacific Group) is a (big) PE firm - ranked third in the PEI 300 ranking of the largest private equity firms in the world. As noted in the press release, the transaction is subject to customary regulatory approvals. There are a lot of reasons to potentially block acquisitions: reduced competition (not a problem here given we're at n=1 of e-prescribing networks), concentration in market power (i.e. they own other similar products), national security concerns (i.e. foreign ownership),and many more. I don't expect any pushback here, but some possible parallels: - DOJ did try unsuccessfully to block the acquisition of Change Healthcare in 2022 with worries of reduced competition in health insurance markets and access to sensitive data. Doesn't have the same flavor here - TPG arguably increases competition by distancing Surescripts from current owners CVS Health and Express Scripts by Evernorth. - Visa attempted to acquire Plaid, but was blocked by the DOJ citing stifling of payments innovation. I'd be curious to see what any lawsuit has to say about Surescripts' innovation that would be further stifled by this. - TPG was blocked by Oregon's public regulator from buying Portland General Electric (woo Portland) from Enron (lol) in 2003. Slightly political in nature and PGE is a utility whereas Surescripts isn't yet viewed in that light. My guess is that any pushback would be akin to the FCC block the PE acquisition of television networks in Standard General - TEGNA. While attributed to market consolidation and labor market disruption, "resistance to M&A" and "PE/hedge fund bad" vibes contributed to the submarining of this deal. Could fuel something here too - people really don't like PE. A PE firm is the best possible path for Surescripts to avoid regulatory scrutiny as opposed to a payer. I am not sure it will change a lot in terms of Surescripts' day-to-day operations or culture, which by all reports is heavily corporate already. Sometimes you see a short term innovation and product innovation "bets" in the first 2-5 years after an investment, which would be cool, but usually you see a squeeze on headcount and other operational efficiencies. Curious for others' thoughts. PE market is newer to me and I don't know TPG's full portfolio quite yet. https://lnkd.in/geVJaqU8
Surescripts has a monopoly over eprescribe networking already and ownership does not change that. This PE change in ownership is much less concerning than CVS, Walgreens, Epic or Oracle buying them.
They have a big healthcare portfolio. They used to own IQVIA, and I think they still have EnvisionRx, a PBM and wellsky
I agree that a payer attempting to acquire Surescripts would invite more scrutiny (see my comments about vertical integration this morning!)… but part of me is still concerned that PE will take what’s become an essential backbone for ePrescribing and monetize or otherwise disrupt its utility in some way.
CVS is splitting its parts off - this could be one oft he first, clear ones to be cleaved off. Heard Oakstreet health is also on the catalog to sell via a PE deal.
Senior Pharmacy Terminologist
1moI personally would like to see innovation in moving from a pharmacy prescription ownership model to a patient ownership model where the patient, if so inclined, would have full control of their prescriptions a la an immutable ledger technology. Prescriber > Patient "Wallet" > Pharmacy